Prospective Grant of Exclusive License for: Silica-Coated Fluorescent Nanodiamond Probes and Devices and Systems for Imaging Fluorescent Nanodiamonds, 34323-34324 [2014-14037]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 115 / Monday, June 16, 2014 / Notices
C. Federal Subaward Reporting System
(FSRS)
This award may be subject to the
Transparency Act subaward and
executive compensation reporting
requirements of 2 CFR part 170.
The Transparency Act requires the
OMB to establish a single searchable
database, accessible to the public, with
information on financial assistance
awards made by Federal agencies. The
Transparency Act also includes a
requirement for recipients of Federal
grants to report information about firsttier subawards and executive
compensation under Federal assistance
awards.
IHS has implemented a Term of
Award into all IHS Standard Terms and
Conditions, NoAs and funding
announcements regarding the FSRS
reporting requirement. This IHS Term of
Award is applicable to all IHS grant and
cooperative agreements issued on or
after October 1, 2010, with a $25,000
subaward obligation dollar threshold
met for any specific reporting period.
Additionally, all new (discretionary)
IHS awards (where the project period is
made up of more than one budget
period) and where: (1) The project
period start date was October 1, 2010 or
after and (2) the primary awardee will
have a $25,000 subaward obligation
dollar threshold during any specific
reporting period will be required to
address the FSRS reporting. For the full
IHS award term implementing this
requirement and additional award
applicability information, visit the
Grants Management Grants Policy Web
site at: https://www.ihs.gov/dgm/
index.cfm?module=dsp_dgm_policy_
topics. Telecommunication for the
hearing impaired is available at: TTY
(301) 443–6394.
emcdonald on DSK67QTVN1PROD with NOTICES
VII. Agency Contacts
1. Questions on the programmatic
issues may be directed to: Michael
Berryhill, Office of Public Health
Support, 801 Thompson Avenue, TMP
Suite 450, Rockville, Maryland 20852,
Telephone: (301) 443–2443, Fax: (301)
443–6048, Email: Michael.Berryhill@
ihs.gov.
2. Questions on grants management
and fiscal matters may be directed to:
Andrew Diggs, Grants Management
Specialist, 801 Thompson Avenue, TMP
Suite 360, Rockville, Maryland 20850,
Phone: (301) 443–2262, Email:
Andrew.diggs@ihs.gov.
3. Questions on systems matters may
be directed to: Paul Gettys, Grant
Systems Coordinator, 801 Thompson
Avenue, TMP Suite 360, Rockville, MD
20852, Phone: (301) 443–2114; or the
VerDate Mar<15>2010
16:36 Jun 13, 2014
Jkt 232001
DGM main line (301) 443–5204, Fax:
(301) 443–9602, Email: Paul.Gettys@
ihs.gov.
VIII. Other Information
The Public Health Service strongly
encourages all cooperative agreement
and contract recipients to provide a
smoke-free workplace and promote the
non-use of all tobacco products. In
addition, Public Law 103–227, the ProChildren Act of 1994, prohibits smoking
in certain facilities (or in some cases,
any portion of the facility) in which
regular or routine education, library,
day care, health care, or early childhood
development services are provided to
children. This is consistent with the
HHS mission to protect and advance the
physical and mental health of the
American people.
Dated: May 30, 2014.
Yvette Roubideaux,
Acting Director, Indian Health Service.
[FR Doc. 2014–13960 Filed 6–13–14; 8:45 am]
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License for: Silica-Coated Fluorescent
Nanodiamond Probes and Devices and
Systems for Imaging Fluorescent
Nanodiamonds
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health
(NIH), Department of Health and Human
Services, is contemplating the grant of
an exclusive worldwide license to
practice the inventions embodied in:
HHS Ref. No. E–175–2012/0 ‘‘Method
for Preparing Silica-Coated
Nanodiamonds;’’ US Provisional Patent
Application 61/672,996 filed July 18,
2012; International Patent Application
PCT/US2013/050779 filed July 17, 2013,
and HHS Ref. No. E–261–2012
‘‘Background-Free Imaging By Selective
Modulation of Nanodiamond
Fluorescence Using A Magnetic Field;’’
US Provisional Patent Application 61/
711,702 filed October 9, 2012 and U.S.
Non-Provisional Patent Application 14/
049,096 filed October 8, 2013 to Bikanta
Corporation, a Delaware Corporation,
having a principal place of business at
6694 Cedar Boulevard, Newark CA
94560.
SUMMARY:
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
34323
The United States of America is an
assignee of the patent rights pertaining
to these inventions.
The contemplated exclusive license
may be in fields of use directed to:
(a) Devices and systems for imaging
magnetically-modulated nanodiamond
probes, and
(b) Sales of silica-coated
nanodiamond probes for non-clinical
uses for a term not to exceed five (5)
years.
DATES: Only written comments and/or
applications for a license that are
received by the NIH Office of
Technology Transfer on or before July
16, 2014 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Michael Shmilovich, Esq, CLP,
Senior Licensing and Patent Manager,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
5019; Facsimile: (301) 402–0220; Email:
shmilovm@mail.nih.gov. A signed
confidential disclosure agreement may
be required to receive copies of the
patent application assuming it has not
already been published under either the
publication rules of either the U.S.
Patent and Trademark Office or the
World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION:
E–175–2012/0
The invention pertains to a robust and
easily implemented method of
synthesizing silica-coated
nanodiamonds for imaging and
therapeutic applications. The method
generally includes coating
nanodiamonds with a silica precursor,
e.g, tetraethylorthosilicate (TEOS),
inside liposomes. The liposomes are
then removed to yield a final product
that is stable, monodisperse, and easy to
functionalize.
E–261–2012/0
The technology pertains to a method
of imaging a biological specimen (e.g.,
human tissue) using fluorescent
nanodiamonds implanted into the
subject of interest, applying a magnetic
field to said subject and producing a
resultant image by a net juxtaposition of
a second acquired image. This process
suppresses the background and permits
selective imaging of the nanodiamonds
in the presence of background
fluorescence that exceeds the signal
from the nanodiamonds. Another aspect
of the invention provides an imaging
E:\FR\FM\16JNN1.SGM
16JNN1
34324
Federal Register / Vol. 79, No. 115 / Monday, June 16, 2014 / Notices
method in which the resulting image is
acquired by applying time-varying
magnetic fields using one or more
secondary image averaged against the
first. The technique relies on imposing
a small (∼100 Gauss) magnetic field on
the sample of interest during optical
imaging combined with post-processing
of the acquired images to remove the
background. This technology can
readily be added onto any commercial
optical imaging platform to achieve
background-free images of the
nanodiamonds in a biological specimen.
The prospective exclusive license will
be royalty-bearing and comply with the
terms and conditions of 35 U.S.C. 209
and 37 CFR part 404. The prospective
exclusive license may be granted unless,
within thirty (30) days from the date of
this published notice, NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: June 11, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–14037 Filed 6–13–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
emcdonald on DSK67QTVN1PROD with NOTICES
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
VerDate Mar<15>2010
16:36 Jun 13, 2014
Jkt 232001
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel; NIAMS
Small Grant Program for New Investigators
(R03).
Date: July 9–10, 2014.
Time: 9:30 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Democracy Boulevard, Suite 800, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Xincheng Zheng, MD,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute of
Arthritis, Musculoskeletal and Skin Diseases,
NIH, 6701 Democracy Boulevard, Suite 800,
Bethesda, MD 20892, 301–594–4953,
xincheng.zheng@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
Dated: June 10, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–13947 Filed 6–13–14; 8:45 am]
Contact Person: Leroy Worth, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, Nat. Institute of Environmental
Health Sciences, P.O. Box 12233, MD EC–30/
Room 3171, Research Triangle Park, NC
27709, (919) 541–0670, worth@niehs.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: June 9, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–13952 Filed 6–13–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Environmental
Health Sciences; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; R13 Review of Conference
Grants.
Date: July 10, 2014.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Environmental
Health Sciences, Keystone Building, 530
Davis Drive, Conference Room 3118,
Research Triangle Park, NC 27709
(Telephone Conference Call).
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; ‘‘NIAID Investigator
Initiated Program Project Applications
(P01)’’.
Date: July 8, 2014.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3117, 6700B Rockledge Drive, Bethesda, MD
20817 (Telephone Conference Call).
Contact Person: Richard W. Morris, Ph.D.,
Scientific Review Officer, Scientific Review
Program, DEA/NIAID/NIH/DHHS, 6700–B
Rockledge Drive, MSC–7616, Room 3251,
Bethesda, MD 20892–7616, 301–451–2663,
rmorris@niaid.nih.gov.
E:\FR\FM\16JNN1.SGM
16JNN1
]]>Agencies
[Federal Register Volume 79, Number 115 (Monday, June 16, 2014)]
[Notices]
[Pages 34323-34324]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-14037]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License for: Silica-Coated
Fluorescent Nanodiamond Probes and Devices and Systems for Imaging
Fluorescent Nanodiamonds
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Institutes of Health (NIH), Department of
Health and Human Services, is contemplating the grant of an exclusive
worldwide license to practice the inventions embodied in: HHS Ref. No.
E-175-2012/0 ``Method for Preparing Silica-Coated Nanodiamonds;'' US
Provisional Patent Application 61/672,996 filed July 18, 2012;
International Patent Application PCT/US2013/050779 filed July 17, 2013,
and HHS Ref. No. E-261-2012 ``Background-Free Imaging By Selective
Modulation of Nanodiamond Fluorescence Using A Magnetic Field;'' US
Provisional Patent Application 61/711,702 filed October 9, 2012 and
U.S. Non-Provisional Patent Application 14/049,096 filed October 8,
2013 to Bikanta Corporation, a Delaware Corporation, having a principal
place of business at 6694 Cedar Boulevard, Newark CA 94560.
The United States of America is an assignee of the patent rights
pertaining to these inventions.
The contemplated exclusive license may be in fields of use directed
to:
(a) Devices and systems for imaging magnetically-modulated
nanodiamond probes, and
(b) Sales of silica-coated nanodiamond probes for non-clinical uses
for a term not to exceed five (5) years.
DATES: Only written comments and/or applications for a license that are
received by the NIH Office of Technology Transfer on or before July 16,
2014 will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Michael Shmilovich, Esq, CLP, Senior Licensing
and Patent Manager, Office of Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-
3804; Telephone: (301) 435-5019; Facsimile: (301) 402-0220; Email:
shmilovm@mail.nih.gov. A signed confidential disclosure agreement may
be required to receive copies of the patent application assuming it has
not already been published under either the publication rules of either
the U.S. Patent and Trademark Office or the World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION:
E-175-2012/0
The invention pertains to a robust and easily implemented method of
synthesizing silica-coated nanodiamonds for imaging and therapeutic
applications. The method generally includes coating nanodiamonds with a
silica precursor, e.g, tetraethylorthosilicate (TEOS), inside
liposomes. The liposomes are then removed to yield a final product that
is stable, monodisperse, and easy to functionalize.
E-261-2012/0
The technology pertains to a method of imaging a biological
specimen (e.g., human tissue) using fluorescent nanodiamonds implanted
into the subject of interest, applying a magnetic field to said subject
and producing a resultant image by a net juxtaposition of a second
acquired image. This process suppresses the background and permits
selective imaging of the nanodiamonds in the presence of background
fluorescence that exceeds the signal from the nanodiamonds. Another
aspect of the invention provides an imaging
[[Page 34324]]
method in which the resulting image is acquired by applying time-
varying magnetic fields using one or more secondary image averaged
against the first. The technique relies on imposing a small (~100
Gauss) magnetic field on the sample of interest during optical imaging
combined with post-processing of the acquired images to remove the
background. This technology can readily be added onto any commercial
optical imaging platform to achieve background-free images of the
nanodiamonds in a biological specimen.
The prospective exclusive license will be royalty-bearing and
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part
404. The prospective exclusive license may be granted unless, within
thirty (30) days from the date of this published notice, NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: June 11, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-14037 Filed 6-13-14; 8:45 am]
BILLING CODE 4140-01-P
